Check our open funding & investment opportunities


REF 0825: Edtech and Medtech. 

πŸ’² Funding: Currently seeking a combination of non-dilutive financing and convertible notes.

βœ… Cap Table: Following the close of a €1M pre-seed round, the Founders retain over 80% equity.

πŸ‘₯ Team: We have 10+ full-time staff and highly engaged top-tier advisors, some of whom have already invested.

πŸ“ Location: Headquartered in Navarra, with presence in Barcelona and Madrid.

πŸ”¬πŸŽ“ Sector: We operate at the intersection of Medtech and Edtech.

🏒 Business Model: Highly scalable, accessible product with a large TAM (Total Addressable Market). Applicable globally to healthcare students/professionals (B2C) and clinics, hospitals & universities (B2B). 

Contact opportunity team

REF 0525: device for Alzheimer, Parkinson and neurodegeneration. 

πŸ’² 100k-300k eur Investment Opportunity: Medical Device for Neurodegenerative Diseases. 

πŸš€Funding sought to develop a medical device enhancing efficacy & safety of therapies for Alzheimer’s, Parkinson’s & related conditions.

βœ… Already validated in animal models. πŸ”œ Now entering human clinical trials

✨ Early-stage investors can participate via a convertible loan note.

Contact opportunity team

REF 0225: novel therapies with IA. 

πŸ’² Required Investment: 5,5M€ Series A round, in two parts: 2M€ in 2025 and 3,5M€ in 2026. Bridge round of up to 400k € in discounted convertible notes available until end of August 2025. Funds will cover preclinical development and manufacturing expenses required to advance the lead candidate to clinical trials in humans.

πŸš€ novel therapeutic products designed with support of cutting-edge IA tools.  Innovative therapeutic approach with AI-designed compounds. Efficacy data in animal models already available. Return: anticipated 20x+ multiplier at exit for investors in this 2025 round. Exit planned for 2030. 

πŸ”¬ Solid scientific foundation, great team, clear development roadmap and long-term vision. 

πŸ“Š Global market, projected to surpass $44B by 2032. 

Contact opportunity team

REF 0325: chemical engineering and green Hydrogen. 

πŸ’² Required Investment: 750,000 €. Funds will cover cash flow for the development, there is a minimum viable product previously developed in collaboration with a Technology Center.

πŸš€Investment Opportunity in Chemical Engineering Project: Efficient Hydrolysis and Green Hydrogen Generation. 

πŸ“ˆ Offered Return: 10% per annum on invested capital (from investment date), structured as debt with an option to convert into equity upon proven profitability.

πŸ›‘οΈ Guarantee: Established company with a solid track record and diversified operations. Holds a granted subsidy amounting to 2.8M €.

Contact opportunity team

REF 0425: Health Artificial Intelligence. 

πŸ’² Required Investment: 150,000 €

πŸš€ Investment Opportunity in Health-tech & artificial intelligence. Innovative company with strong project portfolio and growth potential.

πŸ“ˆ Offered Return: 10% per annum on invested capital (from investment date).

πŸ›‘οΈ Guarantee: Company holds a pending VAT refund (reimbursement expected before end of July).

βœ… Solid foundation and long-term vision.

Contact opportunity team

REF 0525: novel extraction methods for marble quarry. 

πŸ’²  Required investment: 105 M €. Advanced geological studies available. Technical feasibility confirmed (yield: 92% usable material).

πŸš€ Investment Opportunity in marble quarry, open-air with novel extraction methods, ready for production, 4-fold ROI expected within 2 years.

Link to video:  https://dai.ly/k2DC8JizrTRuwjDi0Dk

πŸ“ Exploitation concession currently active. High-potential mining concession active. Proven reserves of 20M tons of cream ivory marble, (premium grade, market value: 120-250 €/mΒ³ as blocks).

Contact opportunity team

Visual aid for optometrists and low-vision patients. REF: 0125

πŸ’² Required Investment: 650,000 €. πŸ“Š More info about the product: https://retiplus.com/en/

πŸš€ Investment Opportunity in Health-tech.  Investment will cover international marketing and expansion.

πŸ“ˆ Offered Return: 15% per annum on invested capital (from investment date).

πŸ“ Currently looking for novel distributors in any country (already selling in Europe, LATAM, EMEA).

βœ… Solid team and long-term market. 

Contact opportunity team